Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Shares Issued (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Shares Issued for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 2.39% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 2.44% increase, with the full-year FY2025 number at $1.6 million, up 2.44% from a year prior.
  • Shares Issued was $1.3 million for Q4 2025 at Phathom Pharmaceuticals, up from $293000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $543.3 million in Q1 2025 to a low of -$543.2 million in Q2 2025.
  • A 4-year average of $2.2 million and a median of $1.3 million in 2025 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 2895.31% in 2024; the steepest drop was 2918.97% in 2024.
  • Phathom Pharmaceuticals' Shares Issued stood at $24.6 million in 2022, then plummeted by 156.7% to -$13.9 million in 2023, then soared by 109.29% to $1.3 million in 2024, then fell by 2.39% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Shares Issued are $1.3 million (Q4 2025), $293000.0 (Q3 2025), and -$543.2 million (Q2 2025).